That’s a good point! And TDL to both RPE and ML.

The email did not request that surprisingly!

Agreed. Sooo overlooked

Of course there are loads of other discoveries outside my areas of interest (eg. Phase Separation in Proteins and its roles in neurodegenerative diseases)... what are your thoughts?

Another one could be related to how we think about gliomas and brain cancers and how neural activity promotes brain tumor growth and resistance. This is a growing 'cancer neuroscience' field and has really important implications for treatment of brain cancers.

Another breakthrough discoveries in my field are optical and chemical actuators (eg. optogenetics/chemogenetics). These have led to a revolution in circuit-based neuroscience and discoveries on how the brain functions. These are just starting to be translated to clinical applications.. we will see?

There seems to be a certain degree of promotion involved in advancing discoveries for certain prizes, which Im not eloquent or articulate enough to describe in a safe way. Maybe someone else is?

It is also one of the fastest translation of fundamental discovery (in 1998) to treatments on the market (eg. suvorexant approved 2014). For more info on the peptides and drugs see DOI: 10.1124/pharmrev.123.000953. I've wondered why this discovery hasn't won big prizes.

I also think that the discovery of orexin/hypocretin is a major breakthrough. This discovery (DOI: 10.1073/pnas.95.1.322 and DOI: 10.1016/s0092-8674(02)09256-5) led new approaches for treatment for narcolepsy and insomnia, new ideas about how arousal and reward systems are intertwined...

It has also changed the stigma around obesity from being a problem of making poor health choices to being a treatable physical illness. This is an interesting (older) article about this...https://www.nytimes.com/2023/01/31/opinion/ozempic-weight-loss-drugs.html. I hope this can happen for addiction.

I think GLP-1 agonists are an exciting and impactful discovery. The fundamental discoveries set the field up for discovery and translation to the variety of commercially available GLP-1 agonists used for diabetes and obesity - with impact in comorbidity.

Congratulations!!!!🎉

Cory Doctorow (who coined the term 'enshittification') is saying exactly the same thing pluralistic.net/2025/09/27/e...